Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
275,000,000
-
Total 13F shares
-
16,580,732
-
Share change
-
+16,580,732
-
Total reported value
-
$366,712,000
-
Price per share
-
$22.40
-
Number of holders
-
46
-
Value change
-
+$366,712,000
-
Number of buys
-
46
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) as of Q3 2020
As of 30 Sep 2020,
Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,580,732 shares.
The largest 10 holders included
FMR LLC, UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO, BlackRock Inc., Artal Group S.A., SANDS CAPITAL MANAGEMENT, LLC, Casdin Capital, LLC, FRANKLIN RESOURCES INC, Alphabet Inc., TYBOURNE CAPITAL MANAGEMENT (HK) LTD, and PERCEPTIVE ADVISORS LLC.
This page lists
46
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.